Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, Taylor JG, Kirby BJ, Dvory-Sobol H, Yang JC, An D, Stamm LM, Brainard DM, Kim S, Krefetz D, Smith W, Marbury T, Lawitz E. Rodriguez-Torres M, et al. Among authors: taylor jg. J Viral Hepat. 2016 Aug;23(8):614-22. doi: 10.1111/jvh.12527. Epub 2016 Mar 9. J Viral Hepat. 2016. PMID: 26957110 Clinical Trial.
Measuring the Influence of Side Effect Expectations, Beliefs, and Incident Side Effects on the Risk for Drug Discontinuation Among Individuals Starting New Medications, a Cross-sectional Study.
Blackburn DF, Yao S, Taylor JG, Alefan Q, Lix LM, Eurich DT, Choudhry NK. Blackburn DF, et al. Among authors: taylor jg. Patient Prefer Adherence. 2024 May 17;18:979-989. doi: 10.2147/PPA.S451012. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 38774475 Free PMC article.
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.
Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG 6th, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Gladwin MT, et al. Among authors: taylor jg 6th. Lancet Haematol. 2024 May;11(5):e345-e357. doi: 10.1016/S2352-3026(24)00045-0. Epub 2024 Mar 27. Lancet Haematol. 2024. PMID: 38554715 Clinical Trial.
Antiviral response and HIV-1 inhibition in sickle cell disease.
Kumari N, Ahmad A, Berto-Junior C, Ivanov A, Wen F, Lin X, Diaz S, Okpala I, Taylor JG, Jerebtsova M, Nekhai S. Kumari N, et al. Among authors: taylor jg. iScience. 2024 Jan 6;27(2):108813. doi: 10.1016/j.isci.2024.108813. eCollection 2024 Feb 16. iScience. 2024. PMID: 38318349 Free PMC article.
Consumer Likelihood to Seek Information on OTC Medicines.
Taylor JG, Ayosanmi OS, Sansgiry SS, Perepelkin JP. Taylor JG, et al. Pharmacy (Basel). 2023 Aug 11;11(4):128. doi: 10.3390/pharmacy11040128. Pharmacy (Basel). 2023. PMID: 37624083 Free PMC article.
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
Dampier CD, Telen MJ, Wun T, Brown RC, Desai P, El Rassi F, Fuh B, Kanter J, Pastore Y, Rothman J, Taylor JG, Readett D, Sivamurthy KM, Tammara B, Tseng LJ, Lozier JN, Thackray H, Magnani JL, Hassell KL; RESET Investigators. Dampier CD, et al. Among authors: taylor jg. Blood. 2023 Jan 12;141(2):168-179. doi: 10.1182/blood.2022015797. Blood. 2023. PMID: 35981565 Free article. Clinical Trial.
240 results